News | June 17, 2008

Bracco Breaks the Mold with Cardiac PET Perfusion Imaging

June 18, 2008 – Bracco Diagnostics showcased its Cardiac PET Perfusion Imaging with CardioGen-82, a Rubidium Rb 82 generator and emphasized the advantages of cardiac PET Perfusion Imaging over the current SPECT, at the Society of Nuclear Medicine's 55th Annual Meeting.

The Rb-82/Sr-82 generator, which is FDA cleared, has Sr-82 on the column. When Sr-82 decays, it decays to a new daughter product called Rb-82. The physical half-life for Rb-82 is 75 seconds, which allows for an efficient protocol. By the time the imaging is completed for the rest portion (approximately 6 minutes), stress can follow immediately and then the stress images can be acquired (approximately 6 minutes). The study can be completed in approximately 40-45 minutes.

Key features of Rb-82 are that it has properties similar to Thallium-201 (Tl-201). Rb-82 acts as a potassium analog, allowing for a high extraction fraction at high flow rates. Defects are visualized within 2 – 7 minutes after injection. Due to the short T_ (75 seconds), both sets of images can be acquired using the same sized dose. A new 100 mCi generator arrives every 28 days. Fixed pricing allows many patients to be performed in a day without the hassle of ordering unit doses. All studies are performed under pharmacologic stress (e.g., adenosine, dipyridamole, or dobutamine)

Some of the advantages of cardiac PET Perfusion Imaging over the current SPECT, according to the company are: improved efficiency; lower radiation; exposure; less attenuation artifacts; and improved resolution.

For more information: www.bracco.com

Related Content

VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
Overlay Init